



DIAGNOS

Your Knowledge Partner

PRESS RELEASE

OTCQB: DGNOF
TSXV : ADK
SOURCE : DIAGNOS Inc.

2019.03.13

DIAGNOS Announces New Agreement in the United Arab Emirates with one of the Largest Pharmaceutical Companies in the World

Brossard, Quebec, Canada – March 13th, 2019 - DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of a significant renewal contract in the United Arab Emirates consisting of a turnkey one-year screening contract for 2 CARA platform services.

So far, DIAGNOS’ healthcare services have been rendered in 16 countries worldwide. During the period covered by the agreement, DIAGNOS estimates that an additional 5,000 patients will be screened in UAE using its CARA platform.

“We are excited to continue our collaboration with one of the largest pharmaceutical companies in the world. More and more we, DIAGNOS and our strategic pharmaceutical partner, are educating governments around the world to our Wellness Program (CARA) and demonstrating the benefits and tremendous cost savings that can be attained from it. We also continue to implement our growth strategy with this key pharmaceutical partner”, said André Larente, President of DIAGNOS.

About DIAGNOS

DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America, is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.

Additional information is available at www.diagnos.com and www.sedar.com

For further information, please contact:

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a



DIAGNOS

Your Knowledge Partner

PRESS RELEASE

OTCQB: DGNOF
TSXV : ADK
SOURCE : DIAGNOS Inc.

result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

– 30 –